Tumor Suppressor Genes
Mostrando 1-12 de 491 artigos, teses e dissertações.
-
1. Prevalence of ERG expression and PTEN loss in a Brazilian prostate cancer cohort
PTEN is the most commonly inactivated tumor suppressor gene in primary prostate cancer (PCa) and its loss is associated with poor clinical outcomes. ERG rearrangement is a genomic alteration frequently found in PCa and its prognostic significance has yielded mixed results. Although the association of PTEN and ERG biomarkers has potential impact on clinical o
Braz J Med Biol Res. Publicado em: 05/12/2019
-
2. Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era
Abstract Germline mutations in BRCA1 and BRCA2 (BRCA) genes confer high risk of developing cancer, especially breast and ovarian tumors. Since the cloning of these tumor suppressor genes over two decades ago, a significant amount of research has been done. Most recently, monoallelic loss-of-function mutations in PALB2 have also been shown to increase the ris
Genet. Mol. Biol.. Publicado em: 29/04/2019
-
3. Decreased expression of chromodomain helicase DNA-binding protein 9 is a novel independent prognostic biomarker for colorectal cancer
Previous studies suggested that chromodomain helicase DNA-binding proteins (CHDs), including CHD 1–8, were associated with several human diseases and cancers including lymphoma, liver cancer, colorectal cancer, stomach cancer, etc. To date, little research on CHD 9 in human cancers has been reported. In this study, we assessed the prognostic value of CHD 9
Braz J Med Biol Res. Publicado em: 23/07/2018
-
4. Tuberous sclerosis complex: review based on new diagnostic criteria
Abstract: Tuberous sclerosis complex is a multisystemic, autosomal dominant genetic disorder with complete penetrance, that can evolve with hamartomas in multiple organs, such as skin, central nervous system, kidney and lung. Due to the wide phenotypic variability, the disease is often not recognized. Tuberous sclerosis complex affects one in 10,000 newborns
An. Bras. Dermatol.. Publicado em: 2018-06
-
5. TSC1 and TSC2 gene mutations and their implications for treatment in Tuberous Sclerosis Complex: a review
Abstract Tuberous sclerosis complex is an autosomal dominant disorder characterized by skin manifestations and formation of multiple tumors in different organs, mainly in the central nervous system. Tuberous sclerosis is caused by the mutation of one of two tumor suppressor genes, TSC1 or TSC2. Currently, the development of novel techniques and great advance
Genet. Mol. Biol.. Publicado em: 20/02/2017
-
6. MicroRNA 100: a context dependent miRNA in prostate cancer
OBJECTIVE: MicroRNAs are noncoding RNA molecules involved in the development and progression of tumors. We have found that miRNA-100 is underexpressed in metastatic prostate cancer compared to localized disease. Conversely higher levels of miR-100 are related to biochemical recurrence after surgery. This suggests that miR-100 may be a context-dependent miRN
Clinics. Publicado em: 2013-06
-
7. Expression profile of microrna-145 in urothelial bladder cancer
PurposeBladder cancer (BC) is the second most common malignancy of the urinary tract, with high mortality. The knowledge of the molecular pathways associated with BC carcinogenesis is crucial to identify new diagnostic and prognostic biomarkers. MicroRNAs (miRNAs) are short non-coding RNA molecules that play important roles in the regulation of gene expressi
Int. braz j urol.. Publicado em: 2013-01
-
8. Prima-1 induces apoptosis in bladder cancer cell lines by activating p53
OBJECTIVES: Bladder cancer represents 3% of all carcinomas in the Brazilian population and ranks second in incidence among urological tumors, after prostate cancer. The loss of p53 function is the main genetic alteration related to the development of high-grade muscle-invasive disease. Prima-1 is a small molecule that restores tumor suppressor function to mu
Clinics. Publicado em: 2013
-
9. Análise do status somático dos genes MEN1, AIP e p27Kip1 em tumores de pacientes com neoplasia endócrina múltipla tipo 1 / Analysis of the status of somatic and p27Kip1 genes in tumors from patients with multiple endocrine neoplasia type 1
Aproximadamente 80% dos casos com Neoplasia endócrina múltipla tipo 1 (NEM1) possuem mutações germinativas no gene supressor de tumor MEN1, que os predispõem a tumores nas glândulas paratireóides, pâncreas endócrino e hipófise, além de outros tumores não endócrinos. A tumorigênese dos mais de 20 diferentes tipos de neoplasias já descritas na N
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 06/06/2012
-
10. Análise molecular dos genes HRPT2 e CICLINA D1 na displasia fibrosa, no fibroma ossificante e no osteossarcoma dos maxilares
Fibrous dysplasia (FD), ossifying fibroma (OF), and osteosarcoma (OS) are examples of bone-related lesions. Recent studies have already shown genetic alterations of the HRPT2 tumor suppressor gene in sporadic and syndromic OF. The present study first sought to raise the hypothesis of whether or not similar alterations would in fact represent one of the under
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 21/05/2012
-
11. The TP53 fertility network
The TP53 gene, first described in 1979, was identified as a tumor suppressor gene in 1989, when it became clear that its product, the p53 nuclear phosphoprotein, was frequently inactivated in many different forms of cancers. Nicknamed "guardian of the genome", TP53 occupies a central node in stress response networks. The p53 protein has a key role as transcr
Genet. Mol. Biol.. Publicado em: 2012
-
12. Pathophysiology and molecular aspects of diffuse large B-cell lymphoma
Diffuse large B-Cell lymphoma is the most common subtype of non-Hodgkin lymphoma in the West. In Brazil, it is the fifth cause of cancer, with more than 55,000 cases and 26,000 deaths per year. At Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - HCFMUSP, diffuse large B-Cell lymphoma represents 49.7% of all non-Hodgkin lymphoma
Rev. Bras. Hematol. Hemoter.. Publicado em: 2012